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Abstract
The question of whether to initiate ART at higher CD4+ cell counts than currently recommended
by World Health Organization (WHO) treatment guidelines received much attention at the XVII
International AIDS Conference (AIDS 2008). If studies presented at the conference ultimately lead
to a revision of WHO treatment guidance, the estimated number of people who will need ART
globally will increase substantially. Task-shifting is emerging as an important strategy for dealing
with the acute shortage of health care workers in many high-burden countries, and several studies
presented at AIDS 2008 demonstrated the impressive health system efficiencies garnered by using
nurses or other health care providers to deliver HIV care and treatment. Other key presentations
and discussion at the conference focused on the optimal time to start TB treatment in HIV-infected
patients, the growing risk of resistance in high-burden countries, including its impact on future
treatment options, and several large cohort trials testing optimal drug regimens in resource-limited
settings.
Biomedical prevention research continues to confirm the long-term, protective benefits of
circumcision. Several studies involving HIV serodiscordant heterosexual couples have produced
data suggesting a strong protective effect of ART for HIV-negative partners. Disappointing results
from recent vaccine and non-ARV based microbicides trials are nevertheless providing important
data to this field, and the expanding number of pre-exposure prophylaxis (PrEP) trials and ARV-
based microbicides appear to provide the best hope for a new, efficacious biomedical prevention
intervention.
Discussion
AIDS 2008, of course, took place two years before the
deadline for universal access, and significant attention
was devoted to the theme of the conference: Universal
Action Now!, particularly in the context of both increases
in the pace of scaling up treatment and care interventions
and the growing realization that few countries are on tar-
get to meet universal access goals. Strategies for improving
access to care in resource-limited countries, the risk of
antiretroviral resistance in these countries, and evolving
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antiretroviral tactics dominated the AIDS 2008 agenda on
clinical research and treatment of HIV infection.
Should ART start at a higher CD4 count?
As AIDS 2008 began, an international panel of treatment
experts convened by the IAS-USA updated antiretroviral
treatment guidelines for adults. The panel recommended
broadening options for starting ART at a CD4 count above
350 cells/mm3 and to include people with active hepatitis
B or C infection, cardiovascular disease risk, or compro-
mised kidney function [1] The panel set no upper CD4
limit on when treatment should begin. A growing data
stream from recent trials suggests that earlier ART may
ward off not only AIDS-defining diseases, but also non-
AIDS cancers and heart, liver, or kidney diseases [2-4].
A cohort study at AIDS 2008 added to accumulating evi-
dence favouring earlier ART. This 1,679-person analysis of
the US HIV Outpatient Study cohort found that a CD4
count under 350 cells/mm3 when first measured inde-
pendently raised the risk of new cardiovascular disease
more than 75% [5] Additional evidence supporting the
clinical value of earlier intervention with antiretrovirals
could lead World Health Organization (WHO) advisors
to review guidelines on when to start ART in resource-lim-
ited countries. WHO currently recommends ART for any-
one with a CD4 count below 200 cells/mm3, while
suggesting clinicians should "consider treatment" for peo-
ple with 200 to 350 cells/mm3 and defer treatment for
people with more than 350 cells/mm3 [6].
During AIDS 2008 incoming IAS President Julio Mon-
taner predicted that revamped treatment guidelines for
high-income countries could "revolutionize the treatment
of HIV" by recognizing HIV infection as a chronic inflam-
matory disease that "affects the heart, liver, kidneys, and
in due course we are going to learn the rest of the assorted
organs in the body" [7,8]. Montaner cautioned that rais-
ing the CD4-cell threshold for starting ART could further
widen the treatment-access gap between developed and
developing countries unless experience confirms his mod-
eling study, which suggests that expanding ART access will
help limit the growth of the HIV epidemic and its associ-
ated costs by reducing infectivity. If this hypothesis proves
true, the preventive effect of ART will be a powerful new
argument for rolling out antiretroviral therapy more
aggressively [9].
Related to the growing debate regarding optimal start and
switch times is the issue of how and what information to
use in clinical decision-making regarding switching drug
regimens. A Haitian study raised concerns about relying
on clinical or immunological criteria to detect ART failure,
based on WHO treatment guidelines, in the absence of VL
and CD4+ laboratory monitoring. In this study almost
half (47%) the participants had HIV RNA levels below the
limit of detection after being assessed as failing ART using
clinical criteria, suggesting that the lack of VL PCR and
other laboratory diagnostics in clinical decision-making
could lead to premature switching [10].
When to start ART in TB co-infected patients
In many parts of the world, tuberculosis is the first AIDS
diagnosis and a leading cause of death among people liv-
ing with HIV. Yet the best time to start ART in HIV/TB-co-
infected individuals remains controversial. Two studies
presented at AIDS 2008 - one in Brazil and one in Argen-
tina - addressed this question but did not reach the same
conclusion.
Valéria Saraceni's 632-person analysis of THRio, a Brazil-
ian observational cohort study, found that starting ART at
any point after beginning anti-TB therapy independently
halved the risk of death, while completing the course of
anti-TB drugs independently lowered the risk of death
more than 85% [11] (Figure 1). A study of 142 HIV/TB co-
infected people in Argentina recorded a higher overall
death rate in those beginning ART within 8 weeks of start-
ing anti-TB medications compared with those starting
ART later (14.4% versus 6.8%, P = 0.013) [12]. However,
TB-related mortality was the same in the two groups, a
pre-ART clinical AIDS diagnosis was twice as common in
the early-ART group, and the investigators did not per-
form multivariate analyses to determine whether the tim-
ing of ART affected mortality independent of other risk
factors. Both of these studies were observational; ongoing
randomized trials to address the optimal time to start ART
during TB treatment are ongoing.
Kaplan-Meier: survival after a TB diagnosis, by exposure to  HAART (Log-rank test-p < .001) Figure 1
Kaplan-Meier: survival after a TB diagnosis, by expo-
sure to HAART (Log-rank test-p < .001). Source: Sara-
ceni, V et al. Tuberculosis, HAART use and survival in the 
THRio Cohort, Rio de Janeiro, Brazil. (MOAB0305)
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The Brazilian study linked delayed HIV diagnosis in TB
patients with a lower chance of receiving ART. That find-
ing underscores the critical need to integrate HIV and TB
care, a policy emphasized in the WHO/IAS/Global Fund/
World Bank consensus statement on knowledge gaps in
the public health approach to delivering ART and care
[13]. The Brazilian investigators recommended universal
opt-out HIV testing for everyone with TB. UNAIDS already
recommends HIV testing and counselling for all TB
patients and screening of all HIV-infected people for TB.
Because TB is such an important co-morbidity throughout
the world, more rigorous prospective research is needed to
optimize the role of ART for co-infected people.
In a post-conference development related to this issue, the
South African chief director of HIV and AIDS, Dr
Nomonde Xundu, confirmed that, as a result of evidence
presented at the conference, a recommendation was
under discussion about potential changes to South
Africa's national treatment guidelines, including whether
to recommend earlier initiation of ART, and whether
additional clinical guidance for individuals co-infected
with TB is also required [14].
Task shifting to widen access to care and treatment
Acute shortages of health professionals remain a stum-
bling block to wider HIV care in many low-income coun-
tries. New research presented by several groups at AIDS
2008 examined the role of task shifting - transferring cer-
tain physician responsibilities to other health workers - as
a way to improve overall access to care.
In Malawi's rural Thyolo district, shifting some counsel-
ling work from nurses to lay counselors - then shifting
ARV initiation duties from physicians to nurses - helped
the region reach universal access targets [15]. The region
has 600,000 people with HIV infection, including 9,000
to 12,000 who urgently needed antiretrovirals, when task
shifting began. Médecins Sans Frontières set an initial tar-
get of treating 10,000 people. Shifting antiretroviral care
duties away from physicians more than doubled the
number of people tested for HIV, and, from 2004 through
2007, boosted the number of people starting ART from
2,000 to 12,000 (Figure 2). Universal access in Thyolo
cost 3 Euros per district inhabitant per year.
A study comparing nurse-led primary care-based ART with
specialist hospital-based care in rural Swaziland docu-
mented lower mortality in the nurse-led setting and com-
parable dropout rates. A separate modeling study
predicting the impact of a pilot task-shifting project in
Rwanda estimated that the number of physicians needed
to provide ART by the end of 2008 will drop from 77 phy-
sicians working 30 hours per week to 17 physicians work-
ing the same number of hours. That change represents a
78% decline in physician demand for HIV care and a
183% gain in physician capacity for non-HIV care (Figure
3).
Task shifting to nurses will not solve ARV access problems
in sub-Saharan Africa because the region also suffers from
a servere shortage of nurses. However, as the study in
Malawi found, certain nursing tasks can be assigned to
other workers, and greater community involvement can
also expand HIV care [16]. By showing that task shifting
may free physicians to manage other diseases, the Rwan-
dan study demonstrates that robust AIDS funding need
not mean neglect of other pressing clinical issues [17].
ART initiation in Thyolo district 2003-2008 Figure 2
ART initiation in Thyolo district 2003-2008. Source: 
Massaquoi, M et al. Achieving universal access to antiretrovi-
ral therapy in a rural district in Malawi: how was it done? 
(TUAB0303).

Roll up to national level Figure 3
Roll Up to national level. Source: Chung, J et al. Quantifi-
cation of physician-time saved in a task shifting pilot pro-
gramme in Rwanda. (WEAB0205)
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Risk of resistance in high-prevalence countries
With respect to ART, one of the most important AIDS
2008 studies assessed the emergence of resistance-related
mutations in Malawi sites that rely on CD4 counts and
clinical symptoms to assess treatment response - because
routine viral load monitoring remains too expensive [18].
Resistance testing of samples from 96 people whose first
ARVs failed uncovered an array of mutations that could
severely compromise nucleoside use in second-line regi-
mens.
Viral load monitoring would have detected ARV failure
earlier and prevented the emergence of many mutations
that developed while these patients continued a failing
regimen. But viral load testing - and often CD4-cell assays
- remain rare in many resource-poor clinics, and their
absence limits optimal ART. Second-line antiretrovirals
are more scarce than first-line agents in many of these
same regions, and rampant resistance will threaten their
use [19]. A recent modeling study by A Phillips (Royal
Free and University College Medical School, United King-
dom) suggested that tracking symptoms and CD4 counts
may do as well as viral load testing in increasing potential
life-years survived in low-income countries [20]. But that
analysis may have underestimated the impact of certain
mutations detected in the Malawi study.
A 2008 consensus statement by WHO, IAS, World Bank
and the Global Fund underscored the need to prioritize
research to address two concerns raised by this study -
determining the optimal time and criteria for switching to
second-line therapy, and defining the most appropriate
use of viral load and CD4-cell monitoring in resource-
constrained regions [21]. The answers to these questions
will be key in shaping the "second wave" of ART rollout
and the clinical approach to treatment and care in low-
and middle-income countries.
Trials of preferred ARV regimens
Many randomized ARV trials recruit patients from across
the globe. Often, however, these trials enrol patients from
the same well-established clinics in low- and middle-
income countries. Rigorously testing promising ARV tac-
tics in diverse settings is critical to establishing their value
in countries with differing demographics and standards of
care. Two ongoing trials tackling this issue were presented
at AIDS 2008.
The multinational PEARLS trial led by the US AIDS Clini-
cal Trials Group set out to compare three first-line regi-
mens in 1,361 adults in Brazil, Haiti, Peru, Malawi, South
Africa, Zimbabwe, India, and Thailand, and 210 adults in
the United States [22]. Patients randomized to once-daily
didanosine, emtricitabine, and atazanavir (without a
ritonavir boost) had a higher risk of treatment failure after
72 weeks than patients randomized to twice-daily zidovu-
dine plus lamivudine and once-daily efavirenz (Figure 4).
Failure rates differed from country to country and were
higher among people with prior or current tuberculosis.
Two points stand out: First, the atazanavir regimen failed
by viral load criteria before clinical failure criteria became
statistically significant - a finding emphasizing the value
of viral load monitoring. Second, although atazanavir is
licensed for use with or without ritonavir, most patients in
the US and Western Europe take the drug with ritonavir to
keep atazanavir concentrations even.
In a recent US trial published before the conference an efa-
virenz-based combination controlled HIV better than
lopinavir/ritonavir in previously untreated people, even
in those starting ART with a viral load above 100,000 cop-
ies/mL [23]. A 48-week Mexican trial led by independent
investigators confirmed better viral control with efavirenz
than with lopinavir/ritonavir in ARV-naive people with
advanced HIV infection (Figure 5) [24]. The Mexican
study enrolled only patients with fewer than 200 CD4
cells/mm3, and the median pre-treatment count stood
well under 100 cells/mm3. Discovery of compelling coun-
try-specific results in such studies should inspire further
randomized controlled trials outside high-income coun-
tries.
Analyzing ART outcomes based on gender and ethnicity
Preliminary results from the Artemis, GRACE and CASTLE
studies were presented at AIDS 2008 where virologic,
immunologic, and safety data from different ARV regi-
mens were analyzed with respect to gender and ethnicity.
All three studies used PI-boosted regimens as treatment
Cumulative probability of treatment failure ddI- EC+FTC+ATV Figure 4
Cumulative probability of treatment failure ddI-
EC+FTC+ATV. Source: Campbell, T et al. ACTG A5175: a 
multinational study of ddI-EC, FTC and atazanavir vs. co-for-
mulated AZT/3TC and efavirenz for initial treatment of HIV-
1 infection. (THAB0404)
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modalities: Artemis compared darunavir/ritonavir to lopi-
navir/ritonavir in treatment-naïve patients at 48 weeks,
GRACE evaluated lopinavir/ritonavir for safety and effi-
cacy in treatment-experienced patients after 24 weeks of
follow-up and the CASTLE study compared atazanavir/
ritonavir with lopinavir/ritonavir in treatment-naïve
patients at 48 weeks [25-28]. At baseline, patient charac-
teristics were comparable across subgroups.
While the three studies varied in cohort size and the rela-
tive distribution of men versus women and ethnic repre-
sentation, all three found no significant difference of
clinical relevance in treatment outcomes (based on viro-
logic suppression and CD4+ count), regardless of treat-
ment modality, between men and women. There were
also no significant differences in adverse events (most
commonly nausea, diarrhea, rash, headaches and weight
gain) when stratified and analyzed by gender, and the
safety and efficacy profile for women in the GRACE study
was comparable to other studies comparing PI-boosted
regimens.
When comparing treatment efficacy and the incidence
and frequency of adverse events among different ethnic
groups, the Artemis study produced comparable results
regardless of race. Ethnicity data from the CASTLE study
indicated that while both treatment modalities in this
study provided promising virologic and immunological
results across ethnic sub-groups, there was some variation
in the magnitude between different ethnic/racial groups,
with ranges of those reaching undetectable levels of
viremia ranging from 71% to 83% in the atazanari/r arm
to 73% to 90% in the lopvinavir/r arm, with the lowest
proportion of those achieving undetectable viremia
among African Americans and the highest proportion
among Asians or Caucasians. Similar immunological
results were reported with respect to CD4+ count
increases. There were modest differences in adverse events
noted, with diarrhea higher among Caucasians (14%)
than among African Americans (5%).
Prevention research
Research into new HIV prevention technologies in the
years leading up to AIDS 2008 has been discouraging.
Between 2006 and 2008, five advanced stage trials (four
for broad-spectrum microbicides and one for a vaccine)
announced nil or negative results, and there are currently
no vaccine candidates ready for field-testing. The long-
term circumcision results reported at AIDS 2008 indicated
that prevention interventions do have the potential to
substantially reduce new infections. Other presentations
mapped out prevention strategies using antiretroviral
agents, which could be introduced in the field relatively
quickly.
More evidence that circumcision works
Most optimistically, Robert Bailey (Chicago School of
Public Health, USA) reported results from extended fol-
low-up of participants in their randomized controlled
trial of male circumcision in Kisumu, Kenya at a late-
breaker session. Previously, participants in the three trials
of circumcision had data up to only 21 - 24 months post-
randomization. Now, with the inclusion of 42 months of
follow-up, Bailey and his colleagues reported a 65% pro-
tective effect of circumcision against HIV acquisition in
young men in Kisumu (Figure 6). The Kisumu trial also
attempted to gauge the effect of circumcision on sexual
pleasure and performance. They found that there was no
appreciable difference between circumcised and uncir-
cumcised men in their reports concerning various meas-
ures of sexual function and satisfaction of female partners
[29].
Bertran Auvert (Hôpitaux de Paris, Université de Versailles
Saint-Quentin, France) presented the results of a study
subsequent to his group's circumcision trial in Orange
Farm, South Africa. After counselling 1,207 men on safe
Virological suppression sratified by baseline CD4+ counts (>/ < 50 cell/mm3) Figure 5
Virological suppression sratified by baseline CD4+ 
counts (>/< 50 cell/mm3). Source: Madero, S. et al. A pro-
spective, randomized, open label trial of efavirenz versus 
lopinavir/ritonavir based HAART among antiretroviral ther-
apy naïve, HIV infected individuals presenting for care with 
CD4 cell counts. (TUAB0104)
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sex and treating them for sexually transmitted infections,
the researchers offered free circumcisions in a medical
clinic. Among the uncircumcised men (68% of the total),
65% eventually accepted the offer [30].
Auvert's group and the Kisumu trial also attempted to
gauge the effect of circumcision on sexual pleasure and
performance. They found that there was no appreciable
difference between circumcised and uncircumcised men,
according to reports from both males and females [31].
Fred Sawe (Kenya Medical Institute/Walter Reed Project
HIV Program, Kenya) in addition reported that HIV pre-
vention and reproductive health training was very well
received during traditional male rites of passage in the
Great Rift Valley [32]. These ceremonies include circumci-
sion. In the interest of safety, medically trained personnel
are increasingly invited to perform the actual circumci-
sions during maturation ceremonies.
Auvert presented the results of the first circumcision rand-
omized clinical trial three years ago at the 3rd IAS Confer-
ence on HIV Pathogenesis and Treatment in Rio de Janeiro
[33]. Studies began reporting a correlation between higher
circumcision rates and lower HIV in parts of Africa 20
years ago [34]. WHO has since then developed a "Male
Circumcision Quality Assurance Guide" providing a
framework for safe mass circumcision programs, includ-
ing infection control and risk reduction guidelines [35].
Yet there are still no large-scale circumcision programmes
for high HIV prevalence areas. Richard White (London
School of Hygiene and Tropical Medicine, United King-
dom) presented a model predicting that in sub- Saharan
Africa, the lowest cost per HIV infection averted in the
next ten years, around US$1,000, would occur if the target
circumcision age group were 25-34 year-olds [36]. This is
the male age range with the highest immediate HIV risk
and somewhat older than the WHO recommended target
group (12-30 year-old males). White and a poster pre-
sented by Agnes Binagwaho (National AIDS Control
Commission, Rwanda) advocated also circumcising new-
borns, although the benefits of doing so would not be vis-
ible for approximately 25 years [37].
Harnessing antiretroviral treatment for prevention
While the implementation of circumcision as a viable pre-
vention strategy lags, a debate has emerged about using
antiretroviral therapy as a prevention tool. In January
2008, Switzerland's Federal Commission on AIDS-
Related Issues (EKAF) released a statement indicating that
people living with HIV who were taking an effective (max-
imally suppressive) antiretroviral regimen could not
transmit the virus [38,39]. There were several strict condi-
tions attached to that position, including at least six
months of undetectable viral load, no other sexually
transmitted disease, and ensuring HIV-negative sex part-
ners were able to make an informed choice to dispense
with condoms.
Nonetheless, arguments ensued over the Swiss statement's
implications at an EKAF-sponsored satellite symposium
that took place just before the official opening of AIDS
2008. EKAF president Pietro Vernazza presented his Com-
mission's point of view, which places the position in a
very carefully-defined context [40]. He said that EKAF was
merely standardizing what physicians were already telling
their patients. In addition, Swiss law is very strict about
exposing other people to HIV, even if transmission does
not occur. Vernazza's point was not that the risk of trans-
mission under suppressive therapy was nil, rather that it
was very small, comparable with the risk of transmitting
while using condoms. Successful ART should therefore be
a reasonable defence against laws criminalizing HIV expo-
sure.
Suzanna Attia (University of Bern, Institute of Social and
Preventive Medicine, Switzerland) presented the results of
a meta-analysis of studies investigating transmission risk
under ART [41]. There have been no studies of patients on
successful ART or in men who have sex with men. There
have been a few studies concerning HIV-discordant heter-
osexual couples in which the HIV-positive partner has an
untreated viral load below 400 copies/mL. One transmis-
sion was noted in a total of approximately 900 patient-
years. Information on condom use and sexually transmit-
ted infections in these studies was unavailable. Attia
Cumulative HIV seroincidence over 42 months by circumci- sion status Figure 6
Cumulative HIV seroincidence over 42 months by 
circumcision status. Source: Bailey, RC et al. The protec-
tive effect of male circumcision is sustained for at least 42 
months: results from the Kisumu, Kenya trial (THAC0501).
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argued for further research before drawing any conclu-
sion.
A randomised controlled trial is currently under way to
quantify the relationship between the level of treatment-
suppressed viral load and HIV transmission. The trial,
sponsored by the US National Institutes of Health, will
follow 1,750 HIV sero-discordant couples assigned to
immediate or deferred treatment. Results will not be avail-
able before 2016, a problematic timeline given the
research suggesting that persons with treatment-sup-
pressed HIV are already reducing their condom use [42].
The tantalizing promise of PrEP
In addition to viewing ART as a potentially effective pre-
vention modality involving those already infected, at the
conference there was also discussion of administering ART
as pre-exposure prophylaxis (PrEP) for HIV-negative per-
sons who are at high risk for infection, including members
of HIV-discordant couples [43]. Although it faced some
activist opposition in the first round of Phase III clinical
trials, when some trials were prematurely halted, support
for the concept has grown, no doubt at least partly due to
the failure of several other biomedical prevention modal-
ities and improvements in the engagement of civil society
in the design and implementation of PrEP clinical trial
protocols.
There are a number of on-going and planned PrEP trials
testing daily regimens (Figure 7). Although PrEP was first
discussed in the mid 1990s, it will be at least four more
years before we see PrEP's benefits fully evaluated in sev-
eral populations using multiple dosing strategies. The util-
ity of intermittent precoital regimens is only now coming
under consideration [44,45]. There was one preliminary
human trial reported at AIDS 2008 involving long-term
injectable PrEP. This trial found than an intramuscular
sustained-release form of rilpivirine (TMC278, a new
reverse transcriptase inhibitor nearing licensure for HIV
treatment) could deliver protective drug levels for over 12
weeks.
There are obvious safety and economic concerns about
supplying antiretroviral drugs to large HIV-negative popu-
lations. If it proves effective, topical application to genital
and anal areas might be more feasible. As conference
attendees heard, tenofovir gel applied locally yields vagi-
nal drug concentrations 100- to 1,000-fold higher than
systemic oral administration [46]. In contrast, blood
Current PrEP trials Figure 7
Current PrEP trials. Source: Mastro, T, Pre-exposure prophylaxis. Overview of current and planned trials (THSY0603).
Current PrEP Trials 
Sponsor/Study Name  Expected
Results 
Product(s) Tested  Sites Status  Study Population 
CDC:
Tenofovir Extended 
Safety Study
2009  Tenofovir  USA (N=400)  Fully enrolled  MSM
NIH: 
MTN-001
2009  Tenofovir 
Tenofovir vaginal 
gel/Both 
South Africa, Uganda, 
US (N=144) 
Enrolling  Women 
CDC:Bangkok Tenofovir 
Study 
2009-2010  Oral tenofovir  Thailand (N=2400)  90% enrolled  Male and female 
injection drug users 
CDC:
TDF-2
2010  Tenofovir + 
emtricitabine 
Botswana (N=2000)  Enrolling  Heterosexual men & 
women 
NIH, Univ. Calif., Gates 
Foundation: iPrEx
2010  Tenofovir + 
emtricitabine 
Brazil, Ecuador, Peru, 
US, other (N=3000) 
Enrolling  MSM
Univ. Washington, Gates 
Foundation: 
Partners PrEP
2011  Tenofovir 
Truvada 
Kenya, Uganda 
(N=3900 couples) 
First sites 
activated
HIV-discordant 
heterosexual couples 
NIH: 
VOICE
2012  Tenofovir 
Tenofovir + 
emtricitabine 
Tenofovir vaginal 
gel 
Malawi, South Africa, 
Uganda, Zambia, 
Zimbabwe 
(N=4200) 
Not yet 
enrolling 
Women 
Family Health 
International: 
FEM-PrEP
2012  Truvada  Kenya, Malawi, South 
Africa, Tanzania 
(N=3900) 
Not yet 
enrolling 
Women Journal of the International AIDS Society 2009, 12(Suppl 1):S4 http://www.jiasociety.org/content/12/S1/S4
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plasma concentrations are more than 10-fold lower with
the gel.
Topical microbicides have not performed well in human
HIV prevention studies, with 10 trials of surfactant and
polyanionic compounds yielding negative results. These
non-specific, broad-spectrum compounds inactivate bac-
teria, viruses and even sperm by emulsifying (surfactants)
or coating (polyanions) their outer layers.
The field is clearly moving forward. AIDS 2008 marked
the shift from broad-spectrum to antiretroviral microbi-
cides [47,48]. Besides the VOICE study testing oral PrEP
versus tenofovir gel, another large, advanced-stage trial
will start in the next two years. This is IPM009, still in its
planning phase. It will study the efficacy of the reverse
transcriptase inhibitor dapivirine, either as a short-acting
vaginal gel or as a long-lasting vaginal ring. The latter is a
new, innovative mechanism for delivering anti-HIV
microbicides. IPM009's sponsor, the International Part-
nership for Microbicides, eventually plans to combine
dapivirine with the licensed entry inhibitor maraviroc.
But the results of many of these trials are not expected
until 2010-12. The only encouraging microbicide in vivo
results at AIDS 2008 came from a small macaque trial of a
vaginal gel, combining two antiretrovirals, tenofovir and
emtricitabine. The trial applied this combination gel 30
minutes before exposure to HIV. Six out of six macaques
were protected from 20 vaginal challenges over ten weeks.
In contrast, seven of eight control macaques became
infected after a median of 3.5 challenges [49].
Vaccines: the role of protective immunity
Recent setbacks in both the vaccine and microbicides field
have required a refocus of research efforts in both fields.
At the conference, Seth Berkley (International AIDS Vac-
cine Initiative, USA) reviewed the International AIDS Vac-
cine Initiative's (IAVI) efforts to screen human subjects for
broadly neutralizing antibodies against HIV [50]. These
antibodies would prevent new cells from becoming
infected and might be the key to a vaccine that creates
"sterilizing immunity" against a wide variety of HIV iso-
lates. Berkley says that advanced mass screening tech-
niques have now permitted IAVI's antibody project to
select promising candidates. Even if such antibodies were
isolated in a few individuals, the problem would remain
how to induce them in the entire human population. A
vaccine based on these antibodies is not expected soon.
Berkley also promoted the concept of using replicating
viral vectors. These vectors would consist of a carrier virus
containing recombinant HIV genes that would induce a
potent immune response.
Current HIV vaccine vectors are all nonreplicating. Among
these is the adenovirus vector used in the Merck vaccine
that yielded negative results in the well-known STEP trial
terminated last year. A US National Institutes of Health
study comparing chimpanzee responses to replicating and
nonreplicating adenovirus-based HIV vaccines was one of
the early warnings about the Merck vaccine design [51].
The replicating adenovirus vector elicited markedly supe-
rior immune responses. Switching to live vectors now will
entail considerable delay as various technical and safety
concerns are resolved.
A new emphasis on prevention cocktails or "combination 
prevention"
Combination prevention strategies was a popular topic of
discussion at the conference [52]. Circumcision pro-
grammes can be combined with condom promotion and
other structural and socio-behavioural approaches to pre-
venting HIV. More detail on combination prevention is
outlined in the following section.
As the Kisumu trial results show, circumcision alone will
not eradicate HIV incidence in men. There is some opti-
mism that adding antiretroviral agents in one of the forms
described above may have a major impact in reducing
incidence. Research is moving forward slowly despite this
potential, and mass implementation will likely also be
slow, if the circumcision experience is any example. The
prevention research legacy of AIDS 2008 is an increasing
recognition that fulfilling the promise of emerging pre-
vention technologies requires a renewed sense of urgency.
Conclusion
AIDS 2008 became known for the "marriage" of treatment
and prevention, with many speakers underscoring the
need to integrate prevention and treatment interventions
to ensure a more effective and sustainable response to
HIV/AIDS. The term 'combination prevention' - the need
to integrate a full range of biomedical, socio-behavioural
and structural interventions is covered in greater detail in
Section 5 of this supplement. New advances in the clinical
management of HIV in resource limited settings and the
success of approaches such as task-shifting could serve as
important models for ART expansion as the HIV field
enters what is increasingly known as the 'second wave' of
ART access. However, cautions regarding the potential
emergence of resistance strains and pressures on health
care systems are highlighting the need for operations
research to ensure the optimal management in treatment
delivery, including ensuring low-cost second line regi-
mens are available.
The vaccine field is returning to the laboratory to assess
different options, such as harnessing the body's innate
immunity using non-replicating viral vectors. But the onlyJournal of the International AIDS Society 2009, 12(Suppl 1):S4 http://www.jiasociety.org/content/12/S1/S4
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two recently proven or promising biomedical interven-
tions at this point are circumcision and ART-based pre-
vention, either as PrEP or as part of increased ART scale-up
that - it is hypothesized - will have a significant impact on
community load and the course of the epidemic.
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